Biomarkers of Anti-VEGF Therapy



As part of ESMO's continuous commitment to offering beneficial educational material relevant to your work and practice in order to receive your certificate, please complete the Evaluation Survey, which will take approximately 5 minutes. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did this E-Learning describe the role of tumor angiogenesis as both a disease mechanism and the therapeutic target in cancers? (1-not at all; 5-a lot)

2. Did your undertaking of this E-Learning allow you to understand a potential role of biomarkers of antiangiogenic activity in cancer treatment? (1-not at all; 5-a lot)

3. Did your undertaking of this E-Learning allow you to discuss challenges in the development of validated biomarkers of antiangiogenic activity? (1-not at all; 5-a lot)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-completely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestions to improve future ESMO E-Learning material, please write in the box below: